NH TherAguix and Jean PERRIN Cancer Centre in Clermont-Ferrand
announce the completion of phase I recruitment and the entry into Phase II for the Nano-GBM phase I/II trial in glioblastoma with the two first patients included.
Archives News
NH TherAguix appoints Vincent Carrère as Chief Executive Officer
NH TherAguix announced the appointment of Vincent Carrère as Chief Executive Officer (CEO).
NH TherAguix announces communications to be presented at the AAPM meeting by Harvard Medical School collaborators
NH TherAguix is happy to announce that 4 communications related to AGuIX will be provided during the American Association for Physicists in Medicine annual meeting in Houston, Texas, USA by our US collaborators
NH TherAguix announces the arrival of Aurélien Meyzaud as Head of Intellectual Property and Business Intelligence
NH TherAguix, a French clinical biotech specialized in the development of innovative nanomedicines for the treatment of cancer by radiotherapy, announces today the arrival of Aurélien Meyzaud as Head of Intellectual Property and Business Intelligence from January 2.
Etude NANORAD 2 : étude clinique pour patients atteints de cancer et présentant des métastases dans le cerveau
NH TherAguix annonce le lancement de la campagne de communication par la société Pivotal, pour aider au recrutement de patients dans l’étude NANORAD2 dont le promoteur est le CHU Grenoble Alpes.
NH TherAguix announces the thesis defense of Dr. Paul Rocchi as the first NHT-funded PhD student
NH TherAguix is pleased and proud to announce that Mr Paul Rocchi successfully defended his thesis, as the first CIFRE PhD student of the company – Oct. 06, 2022.
NH TherAguix announces the arrival of Dr. Olivier de Beaumont as Chief Medical Officer
NH TherAguix (“NHT”), announces today the arrival of Dr. Olivier de Beaumont as Chief Medical Officer from September 2022. – Sept. 09, 2022.
NH TherAguix et le Centre de Lutte Contre le Cancer Jean PERRIN de Clermont- Ferrand annoncent le recrutement du premier patient dans l’essai clinique Nano-GBM de phase I/II ciblant le glioblastome
NH TherAguix et le Centre de Lutte Contre le Cancer Jean PERRIN de Clermont-Ferrand annoncent le recrutement du premier patient de l’étude de phase I/II Nano-GBM ciblant les glioblastomes nouvellement diagnostiqués, étude promue par le Centre Jean PERRIN et dirigée par le Dr Julian Biau, oncologue-radiothérapeute – Grenoble et Clermont-Ferrand (France) – May 13, 2022.
NH TherAguix announces the release of a new clinical batch for it’s drug AGuIX manufactured by CARBOGEN AMCIS
MEYLAN, France, BUBENDORF, Switzerland (November 3rd, 2021) – NH TherAguix, a clinical stage company developing innovative nanomedicine for the treatment of cancer, and CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today the release of a new batch of AGuIX Drug Product for clinical trials.
NH TherAguix reporte son projet d’introduction en bourse sur le marché Euronext Growth à Paris
Grenoble (France), 13 octobre 2021 – L’offre proposée a suscité un intérêt immédiat de la part des investisseurs, conscients du potentiel du candidat-médicament AGuIX® et des besoins médicaux non-satisfaits auquel ce dernier répond. Toutefois, au vu du contexte boursier particulièrement volatil, NH TherAguix a décidé de reporter son projet d’introduction en bourse dans l’attente de conditions de marché plus favorables.
NH TherAguix announces the enrolment in Boston of the first 2 patients in its clinical trials NANOBRAINMETS and NANOSMART
Meylan (France) and Boston (US), October 1st, 2021 – NH TherAguix announces the enrolment of the 2 first patients in its clinical trials NANOBRAINMETS Phase II targeting brain metastasis and NANOSMART Phase Ib/II targeting pancreatic cancer and cancerous lung lesions.
NH TherAguix announces the launch of its IPO on the Euronext Growth market in Paris
Grenoble (France), 28 September 2021 NH TherAguix, French biotech company specialized in the development of innovative nanomedicines for the treatment of cancer by radiotherapy, today announces the launch of its initial public offering with a view to listing its shares on the Euronext Growth market (ISIN code: FR0013105954 – ticket: ALNHT).
NH TherAguix registration document approved by Autorité des Marchés Financiers as part of planned IPO on Euronext Growth Paris
Grenoble (France), 13 September 2021 NH TherAguix, French biotech company specialized in the development of innovative nanomedicines for the treatment of cancer by radiotherapy, today announces the approval of its registration document by the Autorité des marchés financiers (the “AMF”) under number I.21-048 dated 10 September 2021.
NH TherAguix staff member awarded with a Ph.D. prize
NH TherAguix is pleased to announce that Fabien Boux which joined the Clinical Development Unit as Biomedical Engineer in January, was awarded with the Ph. D. prize 2020 of the Société Française de Résonance Magnétique en Biologie et Médecine (“SFRMBM”).
NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial
NH TherAguix and the CHU Grenoble-Alpes announce the publication of the results of the First-In-Human phase 1 clinical trial on the combination of AGuIX with radiotherapy on multiple brain metastases patients – Grenoble (France), May 31, 2021 – 11:00 pm (CET)
€13M A series funding
NH TherAguix, a start-up specializing in nanomedicine for cancer radiotherapy, announces a €13 million round of fundraising, led by Bpifrance – Grenoble/Lyon/Paris (France) – 11 April 2019
Partnership for AGuIX® production with Sanofi
Sanofi and Lyon start-up NH TherAguix team up to produce AGuIX®, an innovative nanoparticle in oncology – Paris (France) – February, 18, 2019